Extremity Cryocompression Therapy for Symptom Relief in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunochemotherapy Including Carboplatin, Taxanes, and Immune Checkpoint Inhibitors
- Conditions
- SCLC
- Registration Number
- JPRN-UMIN000051086
- Lead Sponsor
- Shonan Fujisawa Tokushukai Hospital, Respiratory medicine, Makoto Hibino
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 47
Not provided
1) Presence of peripheral neuropathy with self-reported symptoms (Common Terminology Criteria for Adverse Events: CTCAE grade 2 or higher), excluding those caused by systemic conditions such as diabetes, connective tissue diseases, uremia, vitamin B1 deficiency, cervical or lumbar spondylosis, etc. Objective tests, such as nerve conduction velocity, are not mandatory for excluding peripheral neuropathy. 2) History of Guillain-Barre syndrome or chronic inflammatory demyelinating polyneuropathy. 3) Presence of tumor-related neuropathy. 4) Presence of cognitive impairment or consciousness disturbance preventing completion of the EORTC QLQ-CIPN20 questionnaire. 5) Presence of open wounds or ulcers in the limbs. 6) Severe peripheral arterial disease. 7) Poorly controlled diabetes (HbA1c > 8.0%) at screening. 8) History of Raynaud's phenomenon. 9) Intolerance to cold. 10) Other reasons determined by the principal investigator that render the patient unsuitable for inclusion in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method